Orchid Pharma Limited
NSE: ORCHPHARMA · Pharmaceuticals
Snapshot
Unlock Orchid Pharma Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Orchid Pharma Limited is a pharmaceutical company based in Chennai that specialises in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs), bulk actives, and finished dosage formulations. The company maintains a multi-therapeutic presence across segments including anti-infectives, cardiovascular, and nutraceuticals, while also providing pharmaceutical research and development services.
Business Model
The company generates revenue through the sale of a diverse pharmaceutical portfolio, including oral and injectable cephalosporins, veterinary products, and non-antibiotics. It further monetises its expertise by offering regulatory support, pharmacovigilance, and contract research services to international clients across approximately 40 countries.
- Incorporation Year:1992
- Export Reach:40 countries
Growth Outlook
Growth is expected to be driven by the company's focus on new drug discovery systems and the expansion of its research and development capabilities. Continued penetration into international markets and the leveraging of its diverse therapeutic portfolio remain key strategic priorities.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international regulatory standards and potential audits of its manufacturing facilities.
- Market Competition. Intense competition in the generic pharmaceutical and API sectors may exert pressure on profit margins and market share.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and active pharmaceutical ingredients could impact production costs.
- Currency Risk. As an exporter to approximately 40 countries, the company is exposed to foreign exchange rate volatility affecting its international revenue streams.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Orchid Pharma Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹811 Cr
TTM · consolidated
NET PROFIT
₹20 Cr
TTM · consolidated
EPS
₹4.01
TTM · consolidated
RETURN ON EQUITY
1.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
2.3%
TTM · consolidated
P/E
269.1x
Q4 FY26 · consolidated
EV/EBITDA
76.3x
Q4 FY26 · consolidated
EBITDA MARGIN
9.4%
TTM · consolidated
NET PROFIT MARGIN
10.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Orchid Pharma LimitedORCHPHARMA | 2,615 | 269.06 | 76.30 | -12.0% | 9.4% | 1.6% | 2.3% | +44.1% |
RPG Life Sciences LimitedRPGLIFE | 2,955 | 41.96 | 27.43 | 8.3% | 24.4% | 21.0% | 27.6% | +9.9% |
Gujarat Themis Biosyn Ltd.GUJTHEM | 2,900 | 112.93 | 45.50 | 33.7% | 45.7% | 21.6% | 24.4% | -0.3% |
Gufic Biosciences LimitedGUFICBIO | 2,817 | 60.67 | 27.39 | 15.2% | 16.3% | 10.4% | 15.5% | +1.9% |
Dishman Carbogen Amcis LimitedDCAL | 2,294 | 31.26 | 8.09 | 8.1% | 21.2% | 1.6% | 3.3% | -26.3% |
IOL ChemicalsIOLCP | 2,287 | 34.98 | 16.82 | 11.5% | 12.5% | 8.0% | 11.0% | +75.6% |
As of Q4 FY26
Financials
Orchid Pharma Limited
NSE: ORCHPHARMA · Pharmaceuticals
Snapshot
Unlock Orchid Pharma Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Orchid Pharma Limited is a pharmaceutical company based in Chennai that specialises in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs), bulk actives, and finished dosage formulations. The company maintains a multi-therapeutic presence across segments including anti-infectives, cardiovascular, and nutraceuticals, while also providing pharmaceutical research and development services.
Business Model
The company generates revenue through the sale of a diverse pharmaceutical portfolio, including oral and injectable cephalosporins, veterinary products, and non-antibiotics. It further monetises its expertise by offering regulatory support, pharmacovigilance, and contract research services to international clients across approximately 40 countries.
- Incorporation Year:1992
- Export Reach:40 countries
Growth Outlook
Growth is expected to be driven by the company's focus on new drug discovery systems and the expansion of its research and development capabilities. Continued penetration into international markets and the leveraging of its diverse therapeutic portfolio remain key strategic priorities.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international regulatory standards and potential audits of its manufacturing facilities.
- Market Competition. Intense competition in the generic pharmaceutical and API sectors may exert pressure on profit margins and market share.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and active pharmaceutical ingredients could impact production costs.
- Currency Risk. As an exporter to approximately 40 countries, the company is exposed to foreign exchange rate volatility affecting its international revenue streams.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Orchid Pharma Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹811 Cr
TTM · consolidated
NET PROFIT
₹20 Cr
TTM · consolidated
EPS
₹4.01
TTM · consolidated
RETURN ON EQUITY
1.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
2.3%
TTM · consolidated
P/E
269.1x
Q4 FY26 · consolidated
EV/EBITDA
76.3x
Q4 FY26 · consolidated
EBITDA MARGIN
9.4%
TTM · consolidated
NET PROFIT MARGIN
10.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26